Author: admin

MWC 2025: FOSSiBOT Introduces 7200W Solar Generator and Starlight Night Vision Camera Rugged Phone

Barcelona, Spain – March 4th, 2025 – FOSSiBOT, a new rising star brand from China showcases new feature rugged smartphones, rugged tablets, balcony portable power station, and highest outlet power 7200W home energy solar generator at MWC2025 with booth No.:7D9, Hall 3. As one of the world’s most influential communications and technology events, MWC 2025 brings together top companies and industry leaders from around the world. So what FOSSiBOT brought to this exhibition to show their latest breakthroughs and future vision in the field of intelligent technology?

MWC2025: New concept environment-friendly rugged phone FOSSiBOT F112 Pro

FOSSiBOT F112 Pro: this rugged phone is the industry-first smartphone to adopt liquid silicone gel material which is environmentally friendly. Due to the material, the F112 Pro is skin-friendly soft, colorful, IP68-waterproof, shock-resistance, dustproof and thinner than other clumsy rugged phones. The F112 Pro is generally a mid-ranger with 8GB RAM+256GB ROM, 50MP+5MP macro cameras, and Dimensity 6300 5G processor. The F112 Pro will be launched soon by middle March, 2025.

MWC2025: Global first starlight night vision camera rugged phone FOSSiBOT F107 Pro

FOSSiBOT F107 Pro: for the first time, FOSSiBOT combines starlight night vision camera with smartphones. The starlight night vision camera is mostly used in car’s reversing imaging or full color supervisory control cameras, but now, it’s on the F107 Pro. The starlight night vision camera generates full color images with slight star light, the darker the environment is, the better photo effect it will take. In one word: you can take a full color photo like daylight in super dark environment. Besides the starlight night vision camera, the F107 Pro will come with a 28000mAh huge battery and a strong lumen flashlight torch. The F107 Pro is expected to go to market by May 2025. At FOSSiBOT booth 7D9, many visitors are eager to experience the F107 Pro’s starlight night vision camera.

MWC 2025: The highest output power 7200W power station F7200.

FOSSiBOT F7200: as the name it suggests, the F7200 offers 7200W constant AC output power which is the highest in the market. It will come with 5.22kwh capacity power with EV-grade lifepo4 battery. By AC+solar panels charge simultaneously, the 5.22kwh power will be fully recharged in just 1.5 hours. With such huge capacity and high output power, the F7200 is suitable for off-grid living, home backup power and RV living. This will be a new energy product that maximizes the use of solar energy

MWC2025: New balcony power station FBP1200

FOSSiBOT FBP1200: it offers a whole system of generating solar power by solar panels>store electricity>using electricity in household. The FBP1200 offers 800W max AC output power to household appliances intelligently with wall socket connected, saving energy bills and contribute to environment with sustainable green energy. If you are willing to go outside for camping, the FBP1200 offers 1200W max AC output power.

Besides the above 4 products, FOSSiBOT also brings their hot sellers rugged phones like F109, F106 Pro, and hot sellers power stations like FOSSiBOT F2400, FOSSiBOT F1200 and FOSSiBOT F3600 Pro. Fossibot has always been committed to combining technological innovation with sustainable development. We believe that the future of technology is not only about innovation, but also about responsibility. Fossibot will continue to promote the development of green technology and provide users around the world with more environmentally friendly and sustainable smart products.

For more products, keep an eye on FOSSiBOT social media or visit booth 7D9, hall 3 at Barcelona MWC2025.

Media Contact
Company Name: FOSSiBOT
Contact Person: Joanna Chen
Email: Send Email
Country: China
Website: www.fossibot.com

Austin Technology Celebrates Honors For Perth’s Best IT Company Award 2025

Austin Technology Celebrates Honors For Perth’s Best IT Company Award 2025
MSP Pie is a prestigious organization committed to acknowledging excellence in the IT services sector. Each year, they bestow awards upon companies that demonstrate exceptional innovation, quality, and sustainable practices. By doing so, MSP Pie establishes a benchmark for success and ongoing development within the industry.

Perth, Australia – March 4, 2025 – Austin Technology is Perth’s dependable IT company, armed with a team of seasoned experts and a dedication to swift action. Their services extend beyond simple troubleshooting; they take a proactive approach to managing clients’ IT systems. In the event of any issues, they conduct thorough investigations to pinpoint the cause and prevent future occurrences.

Austin Technology has established itself as a powerhouse in the highly competitive IT scene of Perth. Through their unwavering dedication to providing comprehensive and innovative solutions that cater to various business demands, they have solidified their position as leaders in the industry. Perth’s Best IT Company Award 2025 was bestowed upon them following a rigorous evaluation, which emphasized their expertise in driving digital progress and empowering enterprises through the utilization of advanced technology.

Austin Technology’s Core Values and Distinctive Strengths:

  • Innovative IT Solutions: The company is renowned for creating custom strategies that address complex IT challenges while propelling businesses towards digital excellence.
  • Customer-Centric Approach: Austin Technology places a high premium on customer satisfaction, ensuring that every client receives personalized service and proactive support.
  • Expert Team and Visionary Leadership: With a team of highly skilled professionals and forward-thinking leaders, Austin Technology is committed to delivering excellence in every project.
  • Sustainable IT Practices: Their approach integrates best practices that not only enhance business performance but also promote long-term sustainability and reliability.

During a recent interview, Alex Thompson, CEO of Austin Technology, made these comments, “Being recognized as Perth’s Best IT Company is a reflection of our team’s dedication and the trust our clients have placed in us.” He went on to say, “Our mission has always been to empower businesses with innovative IT solutions that are both robust and adaptive. This award inspires us to continue pushing the boundaries of what’s possible in technology, ensuring our clients stay ahead in an ever-evolving digital world.”

The Austin Technology difference:

  • Local IT Team: With a team based right here in Perth, they understand our business landscape, and we’re deeply embedded into the local community.
  • Rapid Response Times: Their service desk is renowned for its speed—tickets are triaged and addressed within 15 minutes. This means minimal downtime for businesses, fast solutions to IT issues, and speedy assistance for employees.
  • ACSC Essential 8 Expertise: They prioritize protecting businesses from cyber threats. Their wide range of cyber security services are aligned with the Australian Cyber Security Centre (ACSC) Essential 8 risk mitigation controls to protect clients’ data and IT infrastructure.
  • Proven Track Record: Supporting over 3000 end-users across industries like medical, engineering, nonprofits, and more, they have the experience to handle IT environments of any scale, no matter the tech complexities clients are up against.
  • Customized Solutions: They don’t believe in a one-size-fits-all plan. Their IT services are tailored to meet the specific needs of one’s business, so they get the right support.
  • Certified Microsoft Partner: As a Microsoft Solutions Partner, they have the expertise to manage clients’ Microsoft environment, from integrations and subscription management to advanced support for apps like OneDrive, SharePoint, and Power BI.
  • Technical Knowledge: Their team of experts is fully certified and qualified in various areas of IT. They constantly train to ensure businesses receive the highest security and best IT practices.
  • Future-Proof Your Business: The threat of cyberattacks is real and increasing. It’s vital for businesses to partner with an IT company that understands these threats and is proactive about preventing an attack from occurring.
  • 24/7 Unlimited IT Support: Should clients experience an IT issue, it’s good to know they always have a team of experts on call. No waiting and minimal downtime.

With Austin’s backing, you’ll tap into operational efficiencies that can grow alongside your business, providing a competitive advantage and maximizing the value of your technology investments. Count on them to keep your business ahead by offering solutions specifically crafted to propel growth and bolster resilience.

For complete information, visit: https://austintechnology.com.au/

Media Contact
Company Name: Austin Technology
Contact Person: Media Relations
Email: Send Email
Phone: 1300 787 429
Address:Level 2, 541 Hay St
City: Subiaco
State: WA 6008
Country: Australia
Website: austintechnology.com.au/

SafeTest Solutions 24/7 Drug Testing 24/7 Expands Reliable Drug and DNA Testing Services in Philadelphia

SafeTest Solutions 24/7 Drug Testing 24/7 Expands Reliable Drug and DNA Testing Services in Philadelphia
SafeTest Solutions 24/7 Drug Testing is strengthening its commitment to accurate and confidential testing services by expanding its offerings in Philadelphia. The company provides around-the-clock access to drug and DNA testing, ensuring individuals, businesses, and legal professionals have reliable results whenever needed.

With a growing demand for DNA Testing Philadelphia, SafeTest Solutions 24/7 Drug Testing offers legally admissible and private testing for various purposes. Whether for establishing paternity, verifying biological relationships, or fulfilling legal requirements, the company provides precise and timely results. Each test is conducted in accredited laboratories to ensure the highest standards of accuracy. Services are available for personal, legal, and corporate needs.

SafeTest Solutions 24/7 Drug Testing also specializes in Drug Testing Philadelphia, catering to employers, court-ordered cases, and personal testing needs. The company provides a full range of testing options, including urine, hair follicle, and saliva drug screenings. By offering 24/7 availability, SafeTest Solutions 24/7 Drug Testing ensures individuals and businesses can access reliable testing without delays, supporting workplace safety and legal compliance. Mobile testing options are also available for added convenience.

Additionally, the company assists individuals navigating the immigration process with an Immigration DNA Test in Philadelphia. Many immigration applications require DNA verification to prove familial relationships, and SafeTest Solutions 24/7 Drug Testing streamlines the process with fast, government-approved testing. Experienced professionals handle each case with discretion, ensuring compliance with immigration guidelines while delivering prompt and accurate results. Testing is conducted in certified laboratories, meeting strict federal and international requirements.

SafeTest Solutions 24/7 Drug Testing remains dedicated to providing trusted and accessible testing solutions in Philadelphia. By maintaining strict confidentiality, accuracy, and 24/7 availability, the company continues to be a dependable resource for legal, personal, and workplace testing needs.

For more information or to schedule a test, visit https://www.safetestsolutions.com/ or contact SafeTest Solutions 24/7 Drug Testing at (484) 324-6984.

Media Contact
Company Name: SafeTest Solutions 24/7 Drug Testing
Contact Person: Shackeal Johnson
Email: Send Email
Phone: (484) 324-6984
Address:8400 Bustleton Ave Suite 309
City: Philadelphia
State: PA
Country: United States
Website: https://www.safetestsolutions.com/bustleton

Brian Arteaga Expands Real Estate Holdings and Launches Legal Tech Platform

Investor and entrepreneur Brian Arteaga is making strides in real estate and legal technology with bold expansion moves and innovative solutions. His real estate portfolio spans multi-family and single-family properties across Nevada, Georgia, and Ohio, with planned expansions into Texas and Florida, along with global ventures in Mexico. He is also expanding his hospitality investments with hotel partnerships in Thailand and Mexico, while actively pursuing developments in Batumi, Bali, and Dubai.

As he nears completion of his Juris Doctor (JD) degree, Arteaga is leveraging his legal expertise to address a critical gap in legal services. He founded Legal Match Experts and launched LegallyBrilliant.com, a platform designed to connect individuals with specialized attorneys quickly and efficiently. Many clients struggle to find the right legal representation, often hiring lawyers outside their area of expertise or facing language barriers.

LegallyBrilliant.com simplifies the process by providing free matches with up to three vetted attorneys, ensuring users consult the right experts before making a decision. The platform also offers translation services to bridge language gaps, making legal representation more accessible.

“Too often, people waste time and money on lawyers who aren’t the right fit for their needs,” said Arteaga. “LegallyBrilliant.com changes that by offering a fast, free, and reliable way to connect with specialized attorneys across various fields, from real estate and bankruptcy to personal injury and family law.”

With nationwide coverage and next-day matching, LegallyBrilliant.com is set to transform legal access. The process takes just minutes, saving users time, money, and frustration.

As Arteaga continues expanding his global real estate footprint and disrupting the legal industry, his focus remains on accessibility, efficiency, and innovation.

For more information, visit LegallyBrilliant.com.

About Brian Arteaga

Brian Arteaga is a Beverly Hills, California-based real estate investor, hotel developer, and legal entrepreneur. His real estate portfolio includes properties across the U.S. and Mexico, alongside international hotel partnerships in Thailand and Mexico, with future developments in Georgia, Indonesia, and U.A.E. As the founder of Legal Match Experts and LegallyBrilliant.com, he is revolutionizing how consumers find legal representation. Arteaga is currently completing his Juris Doctor (JD) degree and preparing for the California Bar Exam.

Media Contact
Company Name: LegallyBrilliant.com
Contact Person: Brian Arteaga
Email: Send Email
City: Beverly Hills
State: CA
Country: United States
Website: LegallyBrilliant.com

Halal Empty Capsules Market Hit USD 1.55 Billion by 2029 with 5.4% CAGR

“Prominant players operating in the halal empty capsule market include Lonza (Switzerland), ACG (India), Qualicaps (Roquette Freres) (US), Suheung Co. Ltd. (South Korea), Shanxi Guangsheng Capsule Limited (China), CapsCanada (Lyfe Group) (US), HealthCaps India (India), Nector LifeSciences Ltd. (India), Sunil Healthcare (India), and Natural Capsules Limited (India) among others.”
Browse 123 market data Tables and 40 Figures spread through 154 Pages and in-depth TOC on “Halal Empty Capsules Market by Type (Gelatin, Non-gelatin), Application (Pharmaceutical Industry, Nutraceutical Industry, Cosmetic Industry), Competitive Landscape, Region (North America, Europe, APAC, LATAM, Middle East & Africa) – Global Forecast to 2029

The global halal empty capsules market is projected to grow from USD 1.19 billion in 2024 to USD 1.55 billion by 2029, at a CAGR of 5.4%. This growth is driven by rising demand for halal-certified products in the pharmaceutical and nutraceutical sectors, particularly in regions like Asia and the Middle East. The increasing consumer preference for plant-based, non-gelatin capsules made from materials like HPMC and pullulan is also fuelling market expansion. However, the market faces challenges such as limited availability of halal-certified raw materials and varying halal certification requirements. Key players like Lonza, ACG, and Capsugel are focusing on expanding production capabilities to meet growing demand, with North America leading the market in 2023 and the Asia Pacific region anticipated to see the highest growth during the forecast period. The nutraceutical industry, driven by demand for health supplements, is expected to grow significantly.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=166042038

Browse in-depth TOC on “Halal Empty Capsules Market“

123 – Tables

40 – Figures

154 – Pages

The type of segment is segmented into gelatin and non-gelatin. The gelatin halal empty capsules segment dominated type segments owing to various factors such as availability of bovine gelatin, particularly from halal-certified suppliers, and their widespread use, affordability, and ease of production. The non-gelatin segment is anticipated to grow at a significant CAGR owing to the rise in demand for vegan products by consumers in developed countries.

Based on application, the global halal empty capsules market is segmented into pharmaceutical industry, nutraceutical industry, and other end users. The pharmaceutical industry segment held a dominant share in the halal empty capsules market in 2023, and the nutraceutical segment is expected to grow at a highest CAGR during the forecast period of 2024-2029. Increasing demand for pharmaceutical products complying with dietary laws and shift of pharmaceutical companies towards halal-certified production with an aim to cater to a broader customer base.

The market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America dominated the halal empty capsules market in 2023, and the Asia Pacific region is likely to grow at a significant CAGR during the forecast period. The growth of the Asia Pacific region is attributable to the presence of major empty capsule manufacturers in the region. Furthermore, APAC countries also act as key exporters of halal empty capsules to other regions, such as the Middle East, Africa, and Europe, with an increased demand for halal-compliant products.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=166042038

The market for halal empty capsules market is consolidated, with key players strategizing to capture most of the market. Prominent players in the halal empty capsules market are Lonza (Switzerland), ACG (India), Qualicaps (Roquette Freres) (US), Suheung Co. Ltd. (South Korea), Shanxi Guangsheng Capsule Limited (China), CapsCanada (Lyfe Group) (US), HealthCaps India (India), Nector LifeSciences Ltd. (India), Sunil Healthcare (India), and Natural Capsules Limited (India) among others.

Capsugel (Lonza) is one of the leaders in halal empty capsules with extensive product range, including vegetarian and gelatin halal empty capsules. The major strengths of the company include strong global presence in several regions and very high halal and global accepted quality. To maintain its leading position in the halal empty capsules market, the company has adopted organic and inorganic growth strategies. For instance, in November 2022, Capsugel launched the Capsugel Enprotect capsule, a coating-free capsule for intestinal drug delivery.

ACG is one of the dominant players in the global halal empty capsule market. The company offers a wide range of halal capsules, including gelatin and non-gelatin types, such as HPMC (hydroxypropyl methylcellulose) capsules. The company has a strong position in around 138 countries worldwide. ACG has a production capacity of producing 140 billion capsules annually. The company strongly focuses on expanding production capacity in order to meet customer demand. As of December 2023, ACG invested around USD 6 billion to set up a greenfield project for cellulose capsule raw material in Aurangabad, Maharashtra, India.

Schenug Co.Ltd is one of the leading players in the global halal empty capsules market. The company operates in the empty capsules market through its Embocaps brand, which specializes in manufacturing hard empty capsules. The has a production capacity of producing 50 billion capsules annually. The company has a geographic presence across various regions globally.

For more information, Inquire Now!

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/halal-empty-capsules-market-166042038.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Halal Empty Capsules Market Hit USD 1.55 Billion by 2029 with 5.4% CAGR

Apricorn Donates $80,000 to Plant Churches Across US Cities and Abroad

Apricorn specializes in debt management and contract negotiation, helping clients reduce or eliminate financial obligations. Backed by a team with over a century of combined experience, the firm advocates for improved contract terms across various agreements, including credit card debts, medical bills, payday loans, and timeshare contracts. This company delivers strategic solutions for long-term financial stability.

Sheridan, Wyoming – Faith communities play a vital role in bringing people together, offering support, and fostering hope. Yet, establishing new places of worship in growing urban areas and underserved regions often faces financial and logistical barriers.

Recognizing this need, Apricorn has taken a significant step forward. In 2024, the company donated $80,000 to fund church planting efforts across major U.S. cities and abroad, supporting initiatives that strengthen communities and expand access to faith-based spaces worldwide.

The donation was aimed at helping new churches establish roots in key urban centers and underserved areas. It provided spaces for worship, community support, and outreach.

With faith-based organizations playing a crucial role in social services, mentorship, and local development, the initiative sought to create lasting impact beyond the walls of the church.

“This contribution reflects a fundamental belief that God has blessed us so we can bless others,” says the CEO of Apricorn. “By supporting the planting of churches across the U.S. and beyond, we hope to create spaces where people can find faith, community, and support,” he adds.

This donation sets a precedent for how businesses can contribute to community development beyond traditional philanthropy. By supporting church planting efforts, Apricorn has helped create spaces that serve as places of worship and centers for social support and outreach.

As faith-based organizations continue to play a crucial role in fostering community resilience, initiatives like this highlight the lasting impact that strategic giving can have on both local and global scales.

About Apricorn:

Apricorn deals with financial challenges through contract renegotiation and debt management. With a team experienced in handling complex financial agreements, the firm works on reducing or eliminating obligations tied to credit card debt, medical expenses, payday loans, and timeshare contracts.

Based in Sheridan, Wyoming, Apricorn operates in a legal landscape where contract disputes and financial negotiations have far-reaching implications.

As economic pressures continue to affect individuals and businesses, the firm remains engaged in efforts that shape financial outcomes and contract resolutions across multiple sectors.

Media Contact
Company Name: Apricorn LLC
Contact Person: Michael Wells
Email: Send Email
Phone: 800.603.9414
Country: United States
Website: https://apricornlegal.com/about

Bad Mood Monday Unveils Custom Scrolling Websites That Boost Local Search Traffic by 30%

Bad Mood Monday is a Tulsa-based web design studio specializing in mobile-first, scrolling websites tailored for small businesses. Recognizing that 80% of local search traffic originates from smartphones, the company focuses on creating responsive, fast-loading sites that enhance user engagement and accessibility. Their services encompass branding, digital marketing, graphic design, and website optimization, all aimed at boosting online visibility and customer conversion rates.

Tulsa, OK – Recent data indicates that approximately 66% of user attention on a typical web page is focused below the fold, underscoring the importance of engaging, scroll-friendly website designs.

In response to this user behavior, Tulsa-based web design studio Bad Mood Monday has introduced custom scrolling websites designed to enhance local search traffic for small businesses.

Bad Mood Monday’s scrolling websites are set to align with how users interact with digital content, prioritizing smooth navigation and accessibility on mobile devices.

The studio’s approach moves away from traditional multi-page layouts, instead focusing on continuous scrolling experiences that keep information readily available. The company states that this design will enhance user engagement and help businesses improve their visibility in local search results.

According to sources within the company, businesses using their scrolling websites have seen a 30% increase in local search traffic within 90 days. This shows a shift toward mobile-friendly, search-optimized digital experiences.

Bad Mood Monday offers its custom scrolling websites through three service options: custom websites, website rentals, and website refresh services. The company also provides SEO optimization to help businesses improve their search visibility. Each service focuses on small businesses looking to strengthen their online presence and adapt to changing digital habits.

“People instinctively scroll through content all day on social media,” says R. Gregory Rainey, founder of Bad Mood Monday. “But most business websites still follow outdated designs. We’re building scrolling websites that feel seamless, look stunning, and, most importantly, keep visitors engaged,” he adds.

This transformative design will set a new standard for how small businesses connect with local audiences online. As digital habits continue to evolve, Bad Mood Monday’s scrolling websites show a broader shift toward more intuitive and mobile-friendly web experiences.

About Bad Mood Monday:

Bad Mood Monday is a Tulsa-based web design studio specializing in mobile-first, scrolling websites for small businesses.

Their services include custom websites, website rentals, website refreshes, and SEO optimization, all designed to increase online visibility and user engagement. This brand helps clients effectively reach and convert their target audiences by focusing on responsive, mobile-first designs.

Media Contact
Company Name: Bad Mood Monday
Contact Person: R. Gregory Rainey
Email: Send Email
Phone: 918-516-1220
Country: United States
Website: https://badmoodmonday.com/#About

Rebuilders Announces the Official Launch of a Groundbreaking Divorce Recovery Course with Expert Coach Nick Meima

A Revolutionary New Program Designed to Help Individuals Heal, Rebuild, and Thrive After Divorce

Rebuilders, a leader in divorce recovery and personal transformation, is thrilled to announce the launch of its brand-new, redesigned and enhanced Divorce Recovery Course—an innovative program designed to guide individuals through the emotional, psychological, and practical challenges of rebuilding life after divorce.

This latest next-level program is based on over 40 years of research and real-life success stories, now updated with cutting-edge coaching techniques, interactive exercises, and a more personalized approach — all led by divorce recovery expert Nick Meima.

After 14 years of successfully running divorce recovery classes and helping thousands reclaim their happiness, Nick Meima and the Rebuilders team have redesigned this course to be more accessible, more impactful, and more results-driven than ever before.

– This is not just another self-help seminar — this is a structured, step-by-step roadmap to transformation.

– Join the first wave of participants in this exciting new launch! – Click here to secure your spot today!

What Makes This Course Different?

– Brand-New Features for 2025!

– Interactive Learning – More than just theory! Engage in real-world exercises and guided self-discovery that create lasting change.

– Expert Coaching & Support – Direct access to Nick Meima, a seasoned divorce recovery coach with 20+ years of experience helping individuals rebuild their lives.

– Updated Course Material – Incorporating the latest insights from psychology, personal development, and relationship science.

– Community & Connection – No one should go through divorce alone. This course connects you with a powerful support network of like-minded individuals.

– On-Demand Access – Learn at your own pace with online tools, live sessions, and flexible learning options that fit your schedule.

– This is more than a class—it’s a transformation experience.

– This is the FIRST TIME this redesigned course is being offered to the public. Be part of something NEW and LIFE-CHANGING!

Who Should Enroll?

This brand-new Rebuilders Divorce Recovery Course is designed for:

– Those struggling with the emotional pain, grief, and isolation after divorce

– Anyone who feels stuck and unsure how to move forward

– Individuals seeking a proven, structured path to healing and self-empowerment

– Those looking for expert guidance, a supportive community, and real results

– If you’ve been waiting for a sign that it’s time to take back control of your life, THIS IS IT.

– Secure Your Spot in This Exclusive Course!

Meet Your Coach: Nick Meima

Nick Meima is a highly experienced divorce recovery expert who has spent over 14 years leading transformational divorce recovery classes. He has personally helped thousands of individuals move beyond heartbreak and into lives filled with confidence, purpose, and joy.

Nick’s Credentials Include:

– Bachelor’s in Psychology- Master’s in Marriage & Family Counseling- Master’s in Gerontology – 8 Years of Spiritual & Psychological Counseling Training – Training in Group Facilitation & Organizational Consulting- 20 Years in Private Practice Helping Individuals Heal & Rebuild

Nick isn’t just an expert—he’s been through divorce himself. He understands firsthand the pain, struggle, and the journey of rebuilding a wonderful life. His newly updated course brings together his decades of experience, research, and compassionate coaching to create the most effective divorce recovery program yet.

About Rebuilders

For over four decades, Rebuilders has been a trusted name in divorce recovery, personal growth, and transformation. Their programs have helped thousands navigate life’s most difficult transitions and emerge stronger, happier, and more fulfilled.

With this newly redesigned divorce recovery course, Rebuilders is once again leading the way in personal transformation, helping individuals heal, grow, and thrive with cutting-edge strategies and expert guidance.

– This is not just another self-help program—it’s a movement.

Be Part of This Groundbreaking Launch!

If you’re ready to move beyond heartbreak, rediscover yourself, and start a bold new chapter in life, this is your chance!

– Limited spots available for this NEWLY LAUNCHED course!

– Click here to enroll now!

For media inquiries, interviews, or additional information, please contact:

– info@rebuilders.net

– (720) 358-9300

– https://rebuilders.net

Media Contact
Company Name: Rebuilders
Email: Send Email
Phone: (720) 358-9300
City: Boulder
State: Colorado
Country: United States
Website: https://rebuilders.net/

Idiopathic Inflammatory Myositis Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Idiopathic Pulmonary Fibrosis Pipeline Insight” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the Idiopathic Inflammatory Myositis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Idiopathic Inflammatory Myositis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in the competitive pharmaceutical landscape with in-depth Pipeline Insights! Discover the latest advancements, key Idiopathic Inflammatory Myositis Companies driving innovation, and the most promising Emerging Drugs shaping the future of treatment. Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Idiopathic Inflammatory Myositis Pipeline Outlook Report

Key Takeaways from the Idiopathic Inflammatory Myositis Pipeline Report

  • In February 2025:- Novartis Pharmaceuticals– A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies (IIM)
  • In February 2025:- Janssen Research & Development LLC– The purpose of this study is to evaluate the efficacy and safety of Nipocalimab versus placebo in participants with active idiopathic inflammatory myopathies (IIM).
  • In February 2025:- Cabaletta Bio– Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), immune-mediated necrotizing myopathy (IMNM), and juvenile idiopathic inflammatory myopathy (JIIM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.
  • In February 2025:- Argenx:- The study duration will be approximately 92 weeks for all participants. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive either empasiprubart or placebo, respectively, during the treatment period (duration of 25 weeks). At the end of the treatment period, all the participants will enter a safety follow-up period (duration of 65 weeks).
  • In February 2025:- Pfizer– The purpose of this study is to understand how the study medicine, dazukibart, works in people with active idiopathic inflammatory myopathies (dermatomyositis [DM] or polymyositis [PM]). Idiopathic inflammatory myopathies are a group of disorders that show inflammation of the muscles used for movement. There are several types of idiopathic inflammatory myopathies, including DM and PM.
  • DelveInsight’s Idiopathic Inflammatory Myositis pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Idiopathic Inflammatory Myositis treatment.
  • The leading Idiopathic Inflammatory Myositis Companies such as FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma Co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd., Ark Biosciences, Ocean Biomedical and others.
  • Promising Idiopathic Inflammatory Myositis Therapies such as Daxdilimab, Belimumab, Baricitinib, Nipocalimab, Glucocorticoids, Froniglutide and others.

Uncover Idiopathic Inflammatory Myositis groundbreaking developments in the drug pipeline with our latest report! Gain exclusive insights into Idiopathic Inflammatory Myositis Clinical Trials, regulatory updates, and Emerging Drugs across multiple therapeutic areas. Learn how leading Idiopathic Inflammatory Myositis Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Idiopathic Inflammatory Myositis Clinical Trials Assessment

Idiopathic Inflammatory Myositis Emerging Drugs Profile

  • Pamrevlumab: FibroGen

Pamrevlumab is a proprietary therapeutic antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. Pamrevlumab represents a potential treatment for a broad array of fibrotic and proliferative disorders that affect organ systems throughout the body. Currently, the drug is in the Phase III stage of its development for the treatment of Idiopathic Pulmonary Fibrosis.

  • Tipelukast: MediciNova

MN-001 (tipelukast) is a novel, orally bioavailable small molecule compound which exerts its effects through several mechanisms to produce its anti-fibrotic and anti-inflammatory activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in fibrosis development and MN-001’s inhibitory effect on 5-LO and the 5-LO/LT pathway is considered to be a novel approach to treat fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. In addition, histopathological data shows that MN-001 reduces fibrosis in multiple animal models. The US Food and Drug Administration (FDA) has granted orphan-drug designation to MN-001 (tipelukast) for treatment of idiopathic pulmonary fibrosis (IPF). Currently, the drug is in the Phase II stage of its development for the treatment of IPF.

  • PLN-74809: Pliant Therapeutics

PLN-74809 is an oral small-molecule dual-selective inhibitor of αvβ6 and αvβ1 integrins for the treatment of IPF. While present at very low levels in healthy tissues, these integrins are upregulated in the lungs of IPF patients where they activate TGF-β, a key driver of the fibrotic process. Blocking these integrins is designed to stop TGF-β activation, potentially halting the growth of scar tissue. PLN-74809 has received Fast Track Designation and Orphan Drug Designation from the US Food and Drug Administration (FDA) in IPF and Orphan Drug Designation from the European Medicines Agency (EMA) in IPF. The company has completed enrollment in the Phase 2a clinical trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF) and announced positive data from the trial.

  • HZN-825: Horizon Pharmaceuticals

HZN-825 is an oral selective LPAR1 antagonist that has shown early signs of clinical impact in systemic sclerosis. LPAR1 signaling has been implicated in fibrosis and inflammation, and preclinical and clinical evidence support the antifibrotic potential of LPAR1 antagonism across multiple organ systems, including both lung and skin. Currently, the drug is in the Phase II stage of its development for the treatment of Idiopathic Pulmonary Fibrosis.

  • Brilaroxazine: Reviva Pharmaceuticals

Brilaroxazine, a novel serotonin-dopamine modulator with multifaceted activities has the potential to treat idiopathic pulmonary fibrosis (IPF). Serotonin (5-HT) signaling plays a key role, via 5-HT2A/2B/7 receptors, in the vasoactive effect on pulmonary arteries and lung myofibroblast actions. Brilaroxazine displays a high affinity and functional activity for the 5-HT2A/2B/7 receptors and moderate affinity for the serotonin transporter. Brilaroxazine’s effects on vascular fibrosis (5-HT2B receptor), proliferation (5-H2A/2B receptor), relaxation (5-HT2A receptor), inflammation (5-HT7 receptor), and pro-inflammatory cytokines have created interest in the potential to treat IPF. Brilaroxazine was evaluated in a bleomycin (BLM)-induced rat model of IPF receiving either brilaroxazine 15 mg twice daily for 21 days starting at day 1 (BT) or at day 10 (BI) and demonstrated efficacy with significant improvements in key endpoints in the bleomycin (BLM)-induced rat model of IPF. Currently, the drug is in the Phase I stage of its development for the treatment of IPF.

The Idiopathic Inflammatory Myositis pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Idiopathic Inflammatory Myositis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Idiopathic Inflammatory Myositis Treatment.
  • Idiopathic Inflammatory Myositis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Idiopathic Inflammatory Myositis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Idiopathic Inflammatory Myositis market.

Explore the dynamic world of drug development with our latest Idiopathic Inflammatory Myositis Pipeline Insights report! From early-stage research to late-phase Idiopathic Inflammatory Myositis Clinical Trials, our analysis covers key Idiopathic Inflammatory Myositis Companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ Idiopathic Inflammatory Myositis Treatment Drugs

Idiopathic Inflammatory Myositis Companies

FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma Co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd., Ark Biosciences, Ocean Biomedical and others.

Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical

Idiopathic Inflammatory Myositis Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

The future of medicine is evolving rapidly! Get detailed insights into ongoing Idiopathic Inflammatory Myositis Clinical Trials, major Companies driving innovation, and the most anticipated Emerging Drugs in the pipeline. Stay updated with the latest Idiopathic Inflammatory Myositis Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Idiopathic Inflammatory Myositis Market Drivers and Barriers, and Future Perspectives

Scope of the Idiopathic Inflammatory Myositis Pipeline Report

  • Coverage- Global
  • Idiopathic Inflammatory Myositis Companies- FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma Co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd., Ark Biosciences, Ocean Biomedical and others.
  • Idiopathic Inflammatory Myositis Therapies- Daxdilimab, Belimumab, Baricitinib, Nipocalimab, Glucocorticoids, Froniglutide and others.
  • Idiopathic Inflammatory Myositis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Idiopathic Inflammatory Myositis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which Idiopathic Inflammatory Myositis Emerging Drugs are set to revolutionize treatment landscapes? Which Idiopathic Inflammatory Myositis Companies are leading the way in drug discovery? Find answers in our latest Idiopathic Inflammatory Myositis Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ Idiopathic Inflammatory Myositis Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Idiopathic Pulmonary Fibrosis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Idiopathic Pulmonary Fibrosis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Pamrevlumab: FibroGen
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Tipelukast: MediciNova
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Brilaroxazine: Reviva Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Idiopathic Pulmonary Fibrosis Key Companies
  21. Idiopathic Pulmonary Fibrosis Key Products
  22. Idiopathic Pulmonary Fibrosis- Unmet Needs
  23. Idiopathic Pulmonary Fibrosis- Market Drivers and Barriers
  24. Idiopathic Pulmonary Fibrosis- Future Perspectives and Conclusion
  25. Idiopathic Pulmonary Fibrosis Analyst Views
  26. Idiopathic Pulmonary Fibrosis Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Idiopathic Inflammatory Myositis Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

H. Hofmeister & Co. Inc. Helps Westwood, NJ & Bergen County Homeowners with Reliable Water Heater Repairs & Replacements

“Reliable water heater repair and replacement – keeping Bergen County homes warm. $100 off now!”
H. Hofmeister & Co. Inc., a trusted plumbing company in Westwood, NJ, is offering $100 off water heater replacements for homeowners in Bergen County. With over 60 years of experience, they provide fast, reliable service for water heater repairs and installations. This limited-time offer helps residents upgrade their hot water systems affordably.

Westwood, NJ – March 4, 2025 – H. Hofmeister & Co. Inc., a trusted plumbing and HVAC company serving Bergen County since 1966, is excited to announce a limited-time offer of $100 off for homeowners looking to replace their water heaters. This exclusive deal is designed to help residents upgrade their hot water systems with efficient, high-quality replacements while saving money.

Expert Water Heater Repair & Replacement Services in Bergen County

As a family-owned and operated plumbing company, H. Hofmeister & Co. Inc. has built a reputation for reliable service, expert craftsmanship, and customer satisfaction. Whether it’s a water heater repair, full water heater replacement, or an upgrade to an energy-efficient model, the company’s licensed professionals ensure top-tier results for homeowners and businesses alike.

“We understand how frustrating it can be when a water heater fails unexpectedly,” says Harold Hofmeister, lead plumber at H. Hofmeister & Co. Inc. “That’s why we’re offering this special discount to make replacements more affordable and keep our community comfortable with reliable hot water.”

Why Homeowners Trust H. Hofmeister & Co. Inc. for Water Heater Services

• 60+ Years of Experience – Trusted plumbing services in Westwood and surrounding areas since 1966.

• Fast & Reliable Repairs – Same-day service for urgent water heater repairs.

• Licensed & Certified Professionals – Plumbing & Heating License #10625 ensures expert workmanship.

• Full-Service Solutions – Repairs, replacements, and upgrades to tank and tankless water heaters.

• Emergency Services Available – 24/7 call-outs for unexpected hot water failures.

For customers dealing with leaks, low hot water pressure, strange noises, or complete water heater failures, the experts at H. Hofmeister & Co. Inc. provide quick diagnostics and cost-effective solutions.

Claim $100 Off Your Water Heater Replacement Today

Homeowners looking to replace their water heaters can take advantage of this limited-time $100 discount by booking a service through the company’s website shared below.

Media Contact
Company Name: H. Hofmeister & Co. Inc.
Contact Person: Harold Hofmeister
Email: Send Email
Phone: 201-666-1118
Address:115 Bergenline Ave
City: Westwood
State: New Jersey 07675
Country: United States
Website: hhofmeisterplumbing.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: H. Hofmeister & Co. Inc. Helps Westwood, NJ & Bergen County Homeowners with Reliable Water Heater Repairs & Replacements